Class information for:
Level 1: BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
17657 588 41.5 84%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
518 3       ANGIOGENESIS//RETINOPATHY OF PREMATURITY//ENDOSTATIN 20826
361 2             ANGIOGENESIS//ENDOSTATIN//VEGF 17372
17657 1                   BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB 588

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BEVACIZUMAB authKW 433807 31% 5% 182
2 METASTATIC BREAST CANCER authKW 165232 12% 4% 71
3 APATINIB authKW 138468 1% 33% 8
4 ASSISTANCE PUBL HOP PARIS TENON address 103859 0% 100% 2
5 MT BREAST GRP address 77892 1% 50% 3
6 HER2 NEGATIVE authKW 58411 1% 19% 6
7 ABT VASKULARE ONKOL METASTASIERUNG address 51930 0% 100% 1
8 ACUTE LOCOREGIONAL TOXICITY authKW 51930 0% 100% 1
9 AFRICAN AMERICAN HISPANIC authKW 51930 0% 100% 1
10 AL NAFEL AREA address 51930 0% 100% 1

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 13426 77% 0% 451
2 Pharmacology & Pharmacy 79 9% 0% 55
3 Medicine, Research & Experimental 54 5% 0% 28
4 Endocrinology & Metabolism 20 4% 0% 21
5 Obstetrics & Gynecology 19 3% 0% 15
6 Medicine, General & Internal 8 4% 0% 21
7 Pathology 5 2% 0% 9
8 Cell Biology 1 3% 0% 18
9 Medical Laboratory Technology 1 1% 0% 3
10 Toxicology 0 1% 0% 6

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ASSISTANCE PUBL HOP PARIS TENON 103859 0% 100% 2
2 MT BREAST GRP 77892 1% 50% 3
3 ABT VASKULARE ONKOL METASTASIERUNG 51930 0% 100% 1
4 AL NAFEL AREA 51930 0% 100% 1
5 ANIMAL GENET INTEGRAT BIOL 51930 0% 100% 1
6 AVASTIN BIOONCOL 51930 0% 100% 1
7 BAYSTATE REG CANC PROGRAM HEMATOL ONCOL 51930 0% 100% 1
8 BIOMED CORDOBA IMIBIC 51930 0% 100% 1
9 BIOSTAT BIOONCOL BIOSTAT 51930 0% 100% 1
10 BREAST CANC WA 51930 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CLINICAL BREAST CANCER 15204 3% 2% 15
2 EJC SUPPLEMENTS 10274 1% 2% 8
3 BREAST CANCER RESEARCH AND TREATMENT 6429 5% 0% 30
4 ANGIOGENESIS 4512 0% 4% 2
5 ONCOLOGIST 3364 2% 1% 12
6 JOURNAL OF CLINICAL ONCOLOGY 2136 4% 0% 26
7 JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA 2108 1% 1% 5
8 NATURE CLINICAL PRACTICE ONCOLOGY 2017 1% 1% 3
9 CLINICAL CANCER RESEARCH 1822 4% 0% 23
10 LANCET ONCOLOGY 1802 1% 0% 8

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 BEVACIZUMAB 433807 31% 5% 182 Search BEVACIZUMAB Search BEVACIZUMAB
2 METASTATIC BREAST CANCER 165232 12% 4% 71 Search METASTATIC+BREAST+CANCER Search METASTATIC+BREAST+CANCER
3 APATINIB 138468 1% 33% 8 Search APATINIB Search APATINIB
4 HER2 NEGATIVE 58411 1% 19% 6 Search HER2+NEGATIVE Search HER2+NEGATIVE
5 ACUTE LOCOREGIONAL TOXICITY 51930 0% 100% 1 Search ACUTE+LOCOREGIONAL+TOXICITY Search ACUTE+LOCOREGIONAL+TOXICITY
6 AFRICAN AMERICAN HISPANIC 51930 0% 100% 1 Search AFRICAN+AMERICAN+HISPANIC Search AFRICAN+AMERICAN+HISPANIC
7 ANTI VEGF MONOCLONAL IGG1 ANTIBODY 51930 0% 100% 1 Search ANTI+VEGF+MONOCLONAL+IGG1+ANTIBODY Search ANTI+VEGF+MONOCLONAL+IGG1+ANTIBODY
8 ANTI VEGF VEGFR DRUGS 51930 0% 100% 1 Search ANTI+VEGF+VEGFR+DRUGS Search ANTI+VEGF+VEGFR+DRUGS
9 BEVACIZUMAB AND WEEKLY PACLITAXEL 51930 0% 100% 1 Search BEVACIZUMAB+AND+WEEKLY+PACLITAXEL Search BEVACIZUMAB+AND+WEEKLY+PACLITAXEL
10 BEVACIZUMAB THERAPY 51930 0% 100% 1 Search BEVACIZUMAB+THERAPY Search BEVACIZUMAB+THERAPY

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 MANSO, L , MORENO, F , MARQUEZ, R , CASTELO, B , ARCEDIANO, A , ARROYO, M , BALLESTEROS, AI , CALVO, I , ECHARRI, MJ , ENRECH, S , ET AL (2015) USE OF BEVACIZUMAB AS A FIRST-LINE TREATMENT FOR METASTATIC BREAST CANCER.CURRENT ONCOLOGY. VOL. 22. ISSUE 2. P. E51 -E60 24 69% 6
2 BOZZA, C , FONTANELLA, C , BUORO, V , MANSUTTI, M , APRILE, G , (2015) NOVEL ANTIANGIOGENIC DRUGS FOR THE MANAGEMENT OF BREAST CANCER: NEW APPROACHES FOR AN OLD ISSUE?.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. VOL. 8. ISSUE 2. P. 251 -265 36 46% 4
3 PUGLISI, F , BISAGNI, G , CICCARESE, M , FONTANELLA, C , GAMUCCI, T , LEO, L , MOLINO, A , SILVA, RR , MARCHETTI, P , (2016) A DELPHI CONSENSUS AND OPEN DEBATE ON THE ROLE OF FIRST-LINE BEVACIZUMAB FOR HER2-NEGATIVE METASTATIC BREAST CANCER.FUTURE ONCOLOGY. VOL. 12. ISSUE 22. P. 2589 -2602 30 48% 0
4 FAKHREJAHANI, E , TOI, M , (2014) ANTIANGIOGENESIS THERAPY FOR BREAST CANCER: AN UPDATE AND PERSPECTIVES FROM CLINICAL TRIALS.JAPANESE JOURNAL OF CLINICAL ONCOLOGY. VOL. 44. ISSUE 3. P. 197 -207 28 41% 16
5 MANSO, L , PALOMO, AG , CARRION, RP , CASSINELLO, J , SANCHO, IG , LOPEZ-MUNIZ, IC , OLIER, C , FERNANDEZ-ARAMBURO, A , LLORCA, C , GONZALEZ, X , ET AL (2015) FACTORS ASSOCIATED WITH THE SELECTION OF FIRST-LINE BEVACIZUMAB PLUS CHEMOTHERAPY AND CLINICAL RESPONSE IN HER2-NEGATIVE METASTATIC BREAST CANCER: ONCOSUR AVALOX STUDY.ANTICANCER RESEARCH. VOL. 35. ISSUE 12. P. 6941 -6950 16 73% 0
6 MILES, D , CAMERON, D , BONDARENKO, I , MANZYUK, L , ALCEDO, JC , LOPEZ, RI , IM, SA , CANON, JL , SHPARYK, Y , YARDLEY, DA , ET AL (2017) BEVACIZUMAB PLUS PACLITAXEL VERSUS PLACEBO PLUS PACLITAXEL AS FIRST-LINE THERAPY FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MERIDIAN): A DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III TRIAL WITH PROSPECTIVE BIOMARKER EVALUATION.EUROPEAN JOURNAL OF CANCER. VOL. 70. ISSUE . P. 146 -155 13 81% 0
7 SINI, V , CASSANO, A , CORSI, D , DE LAURENTIIS, M , GAMUCCI, T , MAURI, M , NASO, G , ROSELLI, M , RUGGERI, EM , TONINI, G , ET AL (2016) BEVACIZUMAB AS FIRST-LINE TREATMENT IN HER2-NEGATIVE ADVANCED BREAST CANCER: PROS AND CONS.TUMORI. VOL. 102. ISSUE 5. P. 472 -480 22 48% 0
8 DANK, M , BUDI, L , PIKO, B , MANGEL, L , ERFAN, J , CSEH, J , RUZSA, A , LANDHERR, L , (2014) FIRST-LINE BEVACIZUMAB-PACLITAXEL IN 220 PATIENTS WITH METASTATIC BREAST CANCER: RESULTS FROM THE AVAREG STUDY.ANTICANCER RESEARCH. VOL. 34. ISSUE 3. P. 1275-1280 11 92% 8
9 MILES, DW , DIERAS, V , CORTES, J , DUENNE, AA , YI, J , O'SHAUGHNESSY, J , (2013) FIRST-LINE BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR HER2-NEGATIVE METASTATIC BREAST CANCER: POOLED AND SUBGROUP ANALYSES OF DATA FROM 2447 PATIENTS.ANNALS OF ONCOLOGY. VOL. 24. ISSUE 11. P. 2773-2780 12 71% 48
10 GAMPENRIEDER, SP , ROMEDER, F , MUSS, C , PIRCHER, M , RESSLER, S , RINNERTHALER, G , BARTSCH, R , SATTLBERGER, C , MLINERITSCH, B , GREIL, R , (2014) HYPERTENSION AS A PREDICTIVE MARKER FOR BEVACIZUMAB IN METASTATIC BREAST CANCER: RESULTS FROM A RETROSPECTIVE MATCHED-PAIR ANALYSIS.ANTICANCER RESEARCH. VOL. 34. ISSUE 1A. P. 227-233 14 64% 14

Classes with closest relation at Level 1


Rank Class id link
1 18265 VANDETANIB//NINTEDANIB//CEDIRANIB
2 14480 BEVACIZUMAB//OVARIAN CANCER//VEGF TRAP
3 17523 VEGF POLYMORPHISM//RS2010963//405G C
4 6121 MICROVESSEL DENSITY//ANGIOGENESIS//MICROVESSEL COUNT
5 14388 METRONOMIC CHEMOTHERAPY//CIRCULATING ENDOTHELIAL CELLS//METRONOMIC
6 1475 VEGF//FLT 1//VEGF RECEPTORS
7 727 SUNITINIB//METASTATIC RENAL CELL CARCINOMA//RENAL CELL CARCINOMA
8 2966 METASTATIC BREAST CANCER//VINORELBINE//DOCETAXEL
9 2563 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
10 18139 SURROGATE ENDPOINT//SURROGATE OUTCOME//PRENTICE CRITERION

Go to start page